PAS
EW icon

Park Avenue Securities’s Edwards Lifesciences EW Stock Holding History

Park Avenue Securities’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.26M Buy
47,077
+38,253
+434% +$3.2M 0.03% 422
2026
Q1 		$707K Buy
8,824
+303
+4% +$25K 0.01% 957
2025
Q4 		$726K Buy
8,521
+3,193
+60% +$262K 0.01% 944
2025
Q3 		$414K Buy
5,328
+1,301
+32% +$102K ﹤0.01% 1279
2025
Q2 		$315K Buy
+4,027
New +$300K ﹤0.01% 1258
2025
Q1 		– Sell
-5,087
Closed -$377K – 1282
2024
Q4 		$377K Sell
5,087
-4,457
-47% -$312K ﹤0.01% 1191
2024
Q3 		$630K Sell
9,544
-13,940
-59% -$1.01M 0.01% 885
2024
Q2 		$2.17M Buy
23,484
+108
+0.5% +$9.56K 0.03% 390
2024
Q1 		$2.23M Sell
23,376
-1,483
-6% -$125K 0.03% 385
2023
Q4 		$1.9M Sell
24,859
-12,272
-33% -$854K 0.03% 394
2023
Q3 		$2.57M Sell
37,131
-8,432
-19% -$678K 0.04% 267
2023
Q2 		$4.3M Sell
45,563
-2,029
-4% -$176K 0.07% 185
2023
Q1 		$3.94M Buy
47,592
+1,350
+3% +$106K 0.07% 181
2022
Q4 		$3.45M Sell
46,242
-654
-1% -$50.4K 0.06% 197
2022
Q3 		$3.88M Sell
46,896
-735
-2% -$70.7K 0.08% 162
2022
Q2 		$4.53M Buy
47,631
+3,279
+7% +$339K 0.09% 146
2022
Q1 		$5.22M Sell
44,352
-5,409
-11% -$607K 0.09% 121
2021
Q4 		$6.45M Buy
49,761
+4,386
+10% +$512K 0.11% 109
2021
Q3 		$5.14M Buy
45,375
+1,386
+3% +$158K 0.1% 104
2021
Q2 		$4.56M Buy
43,989
+2,955
+7% +$279K 0.1% 105
2021
Q1 		$3.43M Buy
41,034
+5,576
+16% +$471K 0.08% 122
2020
Q4 		$3.23M Buy
35,458
+3,868
+12% +$321K 0.09% 104
2020
Q3 		$2.52M Buy
31,590
+4,130
+15% +$322K 0.08% 109
2020
Q2 		$1.9M Buy
+27,460
New +$1.95M 0.07% 125
2020
Q1 		– Sell
-23,937
Closed -$1.86M – 385
2019
Q4 		$1.86M Sell
23,937
-2,136
-8% -$167K 0.08% 107
2019
Q3 		$1.91M Buy
+26,073
New +$1.83M 0.09% 90
2019
Q2 		– Sell
-21,912
Closed -$1.39M – 316
2019
Q1 		$1.39M Buy
+21,912
New +$1.25M 0.08% 93
2018
Q4 		– Sell
-16,923
Closed -$964K – 219
2018
Q3 		$964K Buy
16,923
+3,690
+28% +$180K 0.15% 44
2018
Q2 		$645K Buy
13,233
+1,161
+10% +$54.2K 0.11% 61
2018
Q1 		$545K Buy
12,072
+1,428
+13% +$62K 0.12% 62
2017
Q4 		$396K Buy
10,644
+1,509
+17% +$55.4K 0.1% 61
2017
Q3 		$335K Buy
9,135
+2,454
+37% +$93.6K 0.1% 60
2017
Q2 		$262K Sell
6,681
-2,160
-24% -$78.8K 0.03% 157
2017
Q1 		$278K Buy
+8,841
New +$277K 0.12% 33

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Park Avenue Securities's EW Position: Q2 2026 in Review

Park Avenue Securities increased its Edwards Lifesciences (EW) stake by 434% in Q2 2026, buying an estimated $3.2M and bringing the position to 47,077 shares worth $4.26M. The position accounts for 0.03% of the portfolio, ranked #422.

Park Avenue Securities first reported a position in EW in Q1 2017 and has held it in 34 quarters since. The position peaked at $6.45M in Q4 2021. 372 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Park Avenue Securities held 47,077 shares of Edwards Lifesciences worth $4.26M as of Q2 2026.
  • Park Avenue Securities bought 38,253 Edwards Lifesciences shares in Q2 2026, an estimated $3.2M.
  • Edwards Lifesciences made up 0.03% of Park Avenue Securities's portfolio in Q2 2026, its #422 holding.
  • Park Avenue Securities first reported a position in Edwards Lifesciences in Q1 2017 and has held it in 34 quarters since.
  • Park Avenue Securities's Edwards Lifesciences position peaked at $6.45M in Q4 2021.
  • 372 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.